These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 24930083)

  • 21. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure.
    Kimura K; Momose T; Hasegawa T; Morita T; Misawa T; Motoki H; Izawa A; Ikeda U
    J Cardiol; 2016 May; 67(5):399-405. PubMed ID: 26692119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials.
    Felker GM; Mentz RJ; Adams KF; Cole RT; Egnaczyk GF; Patel CB; Fiuzat M; Gregory D; Wedge P; O'Connor CM; Udelson JE; Konstam MA
    Circ Heart Fail; 2015 Sep; 8(5):997-1005. PubMed ID: 26374918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Efficacy of Tolvaptan in Congestive Heart Failure Patients with and Without Hypoalbuminemia: A Pilot Study.
    Okabe T; Yakushiji T; Igawa W; Ono M; Kido T; Ebara S; Yamashita K; Yamamoto MH; Saito S; Hoshimoto K; Amemiya K; Isomura N; Araki H; Ochiai M
    Cardiovasc Ther; 2015 Oct; 33(5):275-81. PubMed ID: 26122275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serial direct sodium removal in patients with heart failure and diuretic resistance.
    Rao VS; Ivey-Miranda JB; Cox ZL; Moreno-Villagomez J; Ramos-Mastache D; Neville D; Balkcom N; Asher JL; Bellumkonda L; Bigvava T; Shaburishvili T; Bartunek J; Wilson FP; Finkelstein F; Maulion C; Turner JM; Testani JM
    Eur J Heart Fail; 2024 May; 26(5):1215-1230. PubMed ID: 38556717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Additive Tolvaptan vs. Increased Furosemide on Heart Failure With Diuretic Resistance and Renal Impairment　- Results From the K-STAR Study.
    Inomata T; Ikeda Y; Kida K; Shibagaki Y; Sato N; Kumagai Y; Shinagawa H; Ako J; Izumi T;
    Circ J; 2017 Dec; 82(1):159-167. PubMed ID: 28835586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous high-dose furosemide and hypertonic saline solutions for refractory heart failure and ascites.
    Tuttolomondo A; Pinto A; Parrinello G; Licata G
    Semin Nephrol; 2011 Nov; 31(6):513-22. PubMed ID: 22099508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute decompensated heart failure and the cardiorenal syndrome.
    Liang KV; Williams AW; Greene EL; Redfield MM
    Crit Care Med; 2008 Jan; 36(1 Suppl):S75-88. PubMed ID: 18158481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real World Use of Hypertonic Saline in Refractory Acute Decompensated Heart Failure: A U.S. Center's Experience.
    Griffin M; Soufer A; Goljo E; Colna M; Rao VS; Jeon S; Raghavendra P; D'Ambrosi J; Riello R; Coca SG; Mahoney D; Jacoby D; Ahmad T; Chen M; Tang WHW; Turner J; Mullens W; Wilson FP; Testani JM
    JACC Heart Fail; 2020 Mar; 8(3):199-208. PubMed ID: 32035891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction.
    Matsue Y; Ter Maaten JM; Suzuki M; Torii S; Yamaguchi S; Fukamizu S; Ono Y; Fujii H; Kitai T; Nishioka T; Sugi K; Onishi Y; Noda M; Kagiyama N; Satoh Y; Yoshida K; van der Meer P; Damman K; Voors AA; Goldsmith SR
    Clin Res Cardiol; 2017 Oct; 106(10):802-812. PubMed ID: 28540483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decongestive treatment of acute decompensated heart failure: cardiorenal implications of ultrafiltration and diuretics.
    Freda BJ; Slawsky M; Mallidi J; Braden GL
    Am J Kidney Dis; 2011 Dec; 58(6):1005-17. PubMed ID: 22014726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypertonic saline with furosemide for the treatment of acute congestive heart failure: a systematic review and meta-analysis.
    Gandhi S; Mosleh W; Myers RB
    Int J Cardiol; 2014 May; 173(2):139-45. PubMed ID: 24679680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction.
    Matsue Y; Suzuki M; Torii S; Yamaguchi S; Fukamizu S; Ono Y; Fujii H; Kitai T; Nishioka T; Sugi K; Onishi Y; Noda M; Kagiyama N; Satoh Y; Yoshida K; Goldsmith SR
    J Card Fail; 2016 Jun; 22(6):423-32. PubMed ID: 26915749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction.
    Udelson JE; Bilsker M; Hauptman PJ; Sequeira R; Thomas I; O'Brien T; Zimmer C; Orlandi C; Konstam MA
    J Card Fail; 2011 Dec; 17(12):973-81. PubMed ID: 22123358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
    Gheorghiade M; Gattis WA; O'Connor CM; Adams KF; Elkayam U; Barbagelata A; Ghali JK; Benza RL; McGrew FA; Klapholz M; Ouyang J; Orlandi C;
    JAMA; 2004 Apr; 291(16):1963-71. PubMed ID: 15113814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease.
    Uemura Y; Shibata R; Takemoto K; Uchikawa T; Koyasu M; Ishikawa S; Mitsuda T; Miura A; Imai R; Iwamiya S; Ozaki Y; Kato T; Miura T; Watarai M; Murohara T
    Heart Vessels; 2016 Oct; 31(10):1643-9. PubMed ID: 26615607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
    Costello-Boerrigter LC; Smith WB; Boerrigter G; Ouyang J; Zimmer CA; Orlandi C; Burnett JC
    Am J Physiol Renal Physiol; 2006 Feb; 290(2):F273-8. PubMed ID: 16189291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Controlling the flood gates: vaptans, furosemide and the quest for a renal protective diuresis.
    Costello-Boerrigter LC; Burnett JC
    J Card Fail; 2011 Dec; 17(12):990-2. PubMed ID: 22123360
    [No Abstract]   [Full Text] [Related]  

  • 38. Impact of Continuous Administration of Tolvaptan on Preventing Medium-Term Worsening Renal Function and Long-Term Adverse Events in Heart Failure Patients with Chronic Kidney Disease.
    Nakano Y; Mizuno T; Niwa T; Mukai K; Wakabayashi H; Watanabe A; Ando H; Takashima H; Murotani K; Waseda K; Amano T
    Int Heart J; 2018 Jan; 59(1):105-111. PubMed ID: 29332911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction.
    Damman K; Kjekshus J; Wikstrand J; Cleland JG; Komajda M; Wedel H; Waagstein F; McMurray JJ
    Eur J Heart Fail; 2016 Mar; 18(3):328-36. PubMed ID: 26693947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of tolvaptan add-on treatment on patients with heart failure requiring long-term congestion management: A retrospective cohort study using a medical claim database in Japan.
    Kinugawa K; Matsukawa M; Nakamura Y; Aihara M; Sano H
    J Cardiol; 2023 Jul; 82(1):35-42. PubMed ID: 36587792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.